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Chemotherapy in the elderly –  
How intense should treatment be?
Summary
Physiological changes and deficiencies in cognitive pro-
cesses in the elderly have an influence on therapy and 
drug dosage compliance. The consequences of differ-
ences for the outcome of especially chemotherapies are 
neither well nor systematically studied. Existing studies 
though could actually demonstrate age-related differ-
ences in clinical pharmacokinetics. Another problem is 
the increased number of prescribed drugs that are often 
necessary when getting older (polypharmacy) and their 
interference with over-the-counter drugs (OTC) and 
complementary and alternative medicine (CAM). While 
they are often seen as harmless since they require no pre-
scription or are of “natural origin”, they can contain phar-
maceutical active agents. For example green tea is report-
ed to prevent prostate cancer and pre-menopausal breast 
cancer and is therefore often recommended to cancer pa-
tients, but also contains Epigallocatechin gallate (EGCg) 
an active substance which decreases the bio-availability 
of the anti-cancer drugs Bortezomid or Sunitinib. Con-
clusion: a further and more systematic study of age-relat-
ed differences in the outcome of chemotherapies in the 
elderly is necessary. Here especially the kidney function 
requires adaption of treatment regimen. Furthermore 
the interactions with other drugs, in particular over-the-
counter and alternative medicine, need to be better un-
derstood and communicated. 
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Introduction
Little is known about cancer chemotherapy in the elderly. 
There are only a few studies which include patients with can-
cer who at the same time are older than seventy years of age. 
It is a common practice to treat elderly patients according to 
existing protocols for younger patients with reduced doses 
and off the record; the data are not collected and analyzed. 
Outcome of the chemotherapy in the elderly is influenced 
by age-related changes in body composition and normal or-
gan function as well as age related deficiencies in cognitive 
processes. Reduced visual performance and reduced manual 
dexterity in the elderly lead frequently to dosing and com-
pliance errors. Another complicating factor is the increasing 
use of complementary and alternative medicines by elderly 
patients. This article will review the age related changes of 
body function, organ toxicity after chemotherapy in the el-
derly and the potential impact of complementary and alter-
native medicines.
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Defining old is a complex process. The age of 60 or 65, 
roughly equivalent to the age of retirement in most Western 
countries, is said to be the beginning of old age. The aging 
process is of course a biological reality with its own dynamic 
largely beyond individual control. In view of the increasing 
age of the population in industrialized countries, a differen-
tiation by age (61-75 years: elderly persons; 76-90 years of 
age: old persons; above 90 years: very old persons) seems to 
be useful. 
There are age-related changes in body composition such as 
increased body fat that amounts to circa 35% at age 75, re-
duction of total body water that amounts to about 17% at age 
60, and decrease in extracellular liquid, to circa 40% at age 
65. Aside from changes in body composition, there is a re-
duction of normal organ function every year: cardiac output, 
by about 1%; liver size, by 2%; liver blood flow, 1%; kidney 
blood flow, by 1%; tubular function, by 1%, and glomerular 
filtration rate (GFR), by 1ml/min/1,73m2. 
Changes in biological functions in old age lead to conse-
quences for pharmacotherapy. Reduced secretion of gastric 
acid and gastrointestinal tract motility might lead to a re-
duction of bioavailability of certain drugs. Increased body 
fat might change the distribution volume of lipophilic drugs. 
Reduction of albumin concentration might lead to an in-
crease of non-albumin bound drugs. Reduction of GFR and 
tubular secretional function might lead to an accumulation 
of renally eliminated active substances. 
Other age related deficiencies might complicate effective 
chemotherapy in old and very old patients. Reduced mobil-
ity and increased risk of osteoporosis increase the risk and 
the frequency of falls. Impairment of short-term memory 
leads to dosing errors and compliance problems and an in-
creased belief in “tonics”, which might lead to drug interac-
tions. Functional deficiencies, including emotional changes 
reduce the ability for directed and efficient actions and might 
lead to lethargy and non-adherence to treatment schedules. 
Reduced visual performance and reduced manual dexterity 
might lead to orientation problems, dosage errors and man-
ual difficulties with splitting of tablets. 
Polypharmacotherapy leads to particular problems in the 
elderly patient population. According to one study, the 
PRISCUS Project, every health insured older patient is pre-
scribed 3.6 drugs on the average. Over-the-counter (OTC) 
products are added to this number. 25% of the prescribed 
drugs are potentially inadequate medications. [1]
The problem of non-compliance is already evident in twice 
daily (bid) vs. once daily (qd) dosing of medications. Pub-
lished data on other twice daily medications (eg. metformine, 
glipizide, metoprolol) show that adequate adherence (defined 
as greater than 80% of pills taken) may be only 52-65% [11]. 
A Polish study comparing beta-blockers given once daily 
(betaxolol) or twice daily (metoprolol) to patients with sta-
ble angina pectoris showed 58.6% vs. 42.0% for doses taken 
in the correct time window and 77.4% vs. 53.1% for correct 
interdose intervals in favor of the drug taken once daily [8]. 
Hamaker et al. [6] state that currently ongoing trials in hema-
tological malignancies are unlikely to significantly improve 
our knowledge of the optimal treatment of older patients, as 
those outcome measures, that are of primary importance to 
this patient population are still included in only a minority 
of studies. A broader database of chemotherapy data in el-
derly patients is needed to enable the oncologist to deliver 
evidence based and patient focused cancer care. 
The experience with chemotherapeutic agents and their 
pharmacokinetics in patients with old age is limited. Hurria 
and Lichtman [7] analyze clinical pharmacology of cancer 
therapies in older patients in a mini review. In 18 studies old-
er and younger patient groups were compared. When treated 
with Paclitaxel (3 studies), Docetaxel (4 studies), Oxaliplatin 
(1 study), Temozolomide (1 study), Vinorelbine (2 studies), 
5- Fluorouracil (1 study), Capecitabine (1 study), Etoposide 
(3 studies), Doxorubicin (2 studies) only 5/18 studies could 
actually demonstrate age-related differences in clinical phar-
macokinetics, but this remains controversial.
The International Society of Geriatric Oncology (SIOG) ar-
rived at the following recommendations (Table 1) for the ad-
justment of dosing in elderly patients, according to the under-
lying renal function but also including clinical experience [10]. 
INN 90-60 ml/min 60-30 ml/min 30-15 ml/min
Melphalan 100-200 mg/m2 75% 50%
Oxaliplatine 85-100 mg/m2 100% 100%
Fludarabine 25 mg/m2 20 mg/m2 15 mg/m2
Capecitabine 1250 mg/m2 every 12 h 950 mg/m2 every 12 h Contraindicated
Table 1: Dosing adjustment in elderly cancer patients. Recommendations of the International Society of Geriatric 
Oncology (SIOG) according to the underlying renal function [10]
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Kintzel and Dorr [9] recommended dose modification for 
another set of antineoplastic drugs for patients with renal 
dysfunction (Table 2). The dose modification is clearly relat-
ed to the fraction of renally excreted active or toxic moiety 
of the drug. Etoposide with a fraction of 32% requires nearly 
no reduction in patients with a creatinine clearance of 30 ml/
min., whereas methotrexate with a fraction of 77% of renal-
ly excreted or toxic moiety requires a reduction of 50% in 
patients with INN of 45 ml/min. and should not be given to 
patients with lower renal functions. 
INN f 60 ml/min 45 ml/min 30 ml/min
Etoposide 32% 0.85 0.80 0.75
Hydroxyurea 36% 0.85 0.80 0.75
Dacarbazine 41% 0.80 0.75 0.70
Fludarabine 44% 0.80 0.75 0.65
Lomustine (CCNU) 50% 0.75 0.70 -
Bleomycine 62% 0.70 0.60 -
HD-AraC, MTX 77% 0.65 0.50 -
Table 2. Dose modification for antineoplastic drugs in renal dysfunction [9]
Decreased organ functions, besides renal clearance that may 
lead to consequences for pharmacotherapy, are heart func-
tion, with a reduction of myocytes and reduction of dromo-
trophy, eventually: left ventricular ejection function (LVEF) 
that may lead to congestive heart failure and cardiac arrhyth-
mias. Regarding the nervous system, co-morbidities, such as 
Diabetes Mellitus may lead to higher risk for sensory neu-
ropathies. Reduced vital and diffusion capacity of the lung 
may lead to higher risk for lung toxic side-affects. The reduc-
tion of bone marrow reserve may lead to severe cytopenias. 
An increase in fibrinogen concentration may lead to a higher 
risk for venous thromboembolism. 
An older study from von Hoff et al. [12] compares cumula-
tive doses of Doxorubicin on incidence of cardiotoxicity in 
patients aged 40-59 vs. in patients older than 60 years of age. 
There was an increase in cardiotoxicity with all dose ranges 
in the older patient group. This difference was seen in the 
groups that received Doxorubicin every seven days as well as 
in the group that received the drug every three weeks. 








300 0.6 0.9 2.2 3.4
400 0.7 1.2 2.3 4.6
500 1.5 2.3 5.8 8.9
600 3.9 6.1 14.9 22.4
700 8.7 13.2 30.5 43.5
Table 3: Doxorubicin-induced cardiotoxicity (%) related to cumulative dose. Modified from [12].
Newer orally available “targeted” anti-cancer agents are of 
special interest in the elderly patient group. E.c., target pro-
tein produced by bcr-abl fusion gene can be attacked by Im-
atinib (GLIVEC), Dasatinib (SPRYCEL), Nilotinib (TASIG-
NA), Bosutinib (BOSULIF), and Ponatinib (ICLUSIG). The 
epidermal growth factor receptor (EGFR) is target for sev-
eral drugs like Erlotinib (TARCEVA), Imatinib (GLIVEC), 
Afatinib (GILOTRIF), and Lapatinib (TYVERB). Other 
drugs like Sorafenib (NEXAVAR) and Sunitinib (SUTENT) 
interfere with Vascular Endothelial Growth Factor (VEGF). 
Other drugs like Vemurafenib (ZELBORAF) and Dabrafenib 
(TAFINLAR) interfere with mutations of BRAF, the serine/
threonine-protein kinase. Other targeted therapies include 
Crizotinib (XALKORI), Everolimus (AFINITOR), Vismo-
degib (ERIVEDGE), Trametinib (MEKINIST), and Ibruti-
nib (IMBRUVICA) as well as Thalidomide, Lenalidomide 
(REVLIMID), and Pomalidomide (IMNOVID) which in 
partly modulate the immune system. 
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Phytopharmaca Active substance Possible pharmacokintetic interaction
Cranberry fruit
(Vaccinium macrocarpon)
Anthocyane, Flavonoide Cyp (1A2, 2C9, 3A4)- and PgP-inhibition
Garlic 
(Allium sativum)
Allicin, Cyp3A- and PgP-induktion, Cyp2C9, 2C19, 2E1-inhibition
Ginkgo 
(Ginkgo biloba)
Ginkgolide, Flavonoide Cyp3A- induction, free radical scavenger properties; PD: TAH
Ginseng 
(Panax ginseng)
Ginsenoside Cyp3A-induction (& inhibition)
Green tea
(Camellia sinensis)
Catechine (ECG, EGCG) Cyp3A, 2A6, 2C19, 2E1-Inhibition, increased Cyp1A2, 2B and 
NDAPH-Cyp450-reduktase-activity, PgP-inhibition, inhibits 
SULT1A1, SULT1A3 and OATP1A2, OAT1B1, OATP2B1-transport, 
stimulates OATP1B3-transport 
St John´s wort 
(Hypericum perforatum)
Hyperforin, Hypericin et al. Broad spectrum of Cyp- and PgP-induction
Table 4: Possible pharmacokinetic interaction of phytopharmaca with prescription drugs.
Particular attention needs to be directed toward the toxicity 
of targeted anti-cancer therapy in the elderly [5]. The old-
er human population compared to the younger population 
shows more toxicity in several areas. Imatinib shows more 
hematologic and non-hematologic toxicities in older patients. 
Bevacizumab shows more thromboembolism, more fatigue 
and more asthenia. Bortezomib shows more gastrointesti-
nal problems, fatigue and neuropathies. Thalidomide shows 
more deeper vein thrombosis. Lenalidomide needed to be 
discontinued more frequently in the older population related 
to hematological and non-hematological toxicities. No age 
related differences in toxicity were seen in Trastuzumab. 
A well-known example for influencing therapeutically need-
ed drug levels are the Calcineurin inhibitors (CNI). Drugs 
which inhibit the Cytochrome P450 3A4 enzyme system that 
metabolizes CNIs lead to an increased risk for toxicity, drugs 
which induce enzymes catabolizing CNIs lead to a decreased 
drug concentrations and therefore an increased risk of treat-
ment failure. Therefore, close attention needs to be given to 
the drug concentration, particularly if other drugs are given 
which induce or inhibit enzymes. 
A particular problem of drug interference constitutes over-
the-counter (OTC) and complementary and alternative 
medicine (CAM). There are many-fold explanations:
 – OTCs require no prescription, “therefore they cannot be 
dangerous”.
 – There is a need to address personal fears and worries
 – Desire to do something for one’s health
 – Therapy considered to be harmless (natural)
 – Belief: “natural” things are good
 – Can do no harm
 – Strengthen the immune system
 – Intriguing and useful information from friends, fellow suf-
ferers and the Internet.
Complementary and alternative medicine are based on mys-
ticism and magic: 
Mysticism (nature is benign and curing negative damaging 
effects are ignored); Magic (delusions and wishful thinking 
attempt to influence processes outside one’s control).
There are only a few interactions between prescription drugs 
and CAM known and reported. One example is the inter-
action between Imatinib/St. John’s Wort (hypericum perfora-
tum), a Cyp3A-inductor. Frye et al. [3] reported an increase 
of Imatinib-clearance by 43% through the effect of concomi-
tantly given St. John’s Wort. 
Another publication points to probable interaction of etopo-
side with Echinacea [2]. In this case, it was likely that Echi-
nacea contributed to a patient’s profound life-threatening 
thrombocytopenia and therefore should be avoided in pa-
tients receiving etoposide and possible other chemothera-
peutic drugs that are CYP 3A4 substrates. 
Green Tea is widely used as a CAM. It has been reported in 
the treatment of patients with asymptomatic CLL, has been 
reported to induce cell death in AML, has been reported to 
prevent prostate cancer and pre-menopausal breast cancer. 
On the other hand, one of the active agents of green tea, the 
Epigallocatechin gallate (EGCG) decreases the bio-availabil-
ity of Bortezomid, one of the most active agents in the treat-
ment of multiple myeloma [4]. 
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Conclusions
What needs to be generally considered regarding tumor 
therapy in older patients?
Many PK-studies in geriatric patients are contradictory, the 
problem being: small patient numbers, co-factors, analytical 
methods (standardization),
Especially, the kidney function is age-related and requires 
adherence to the treatment guides (e.g. SIOG), 
Age-related co-morbidities and toxicity profiles of the in-
volved active substances need to be correlated,
Polypharmacy (OTC) can create complex interactions in 
older patients. The medical history of an oncology patient 
should include his prescription drugs as well as the compli-
mentary and alternative medicines. 
More attention needs to be directed toward investigating 
these interactions. Education of patients, relatives and sup-
portive staff is critical to achieve this. 
There is a definite need for drug studies in elderly patients. 
It would be a first step if a means could be found to collect 
data from patients above the age cut-off of oncology studies 
when they are treated according to the protocol with or with-
out “age adjustment” of drug doses. A second step may be 
the inclusion of elderly patients by increasing the age limit 
of the studies, and by designing specific chemotherapy stud-
ies for old patients in need of treatment. 
Conflict of interest
All authors have no conflict of interest to declare.
References
1. Amann U, Schmidt N, Garbe E. Prescribing of potentially 
inappropriate medications for the elderly: an analysis based 
on the PRISCUS list. Dtsch Arztebl Int 2012; 109(5): 69-75. 
2. Bossaer JB, Odle BL. Probable etoposide interaction with 
Echinacea. J Diet Suppl 2012;9(2): 90-5. 
3. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egor-
in MJ. Effect of St John’s wort on imatinib mesylate pharma-
cokinetics. Clin Pharmacol Ther 2004; 76(4): 323-9. 
4. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, 
Louie SG, Petasis NA, Chen TC, Schönthal AH. Green tea 
polyphenols block the anticancer effects of bortezomib and 
other boronic acid-based proteasome inhibitors. Blood 2009; 
113(23): 5927-37. 
5. Gonsalves W, Ganti AK. Targeted anti-cancer therapy in 
the elderly. Crit Rev Oncol Hematol 2011; 78(3): 227-42. 
6. Hamaker ME, Stauder R, van Munster BC. Ongoing clin-
ical trials for elderly patients with a hematological malignan-
cy: are we addressing the right end points? Ann Oncol 2014; 
25(3): 675-81. 
7. Hurria A, Lichtman SM. Clinical pharmacology of can-
cer therapies in older adults. Br J Cancer 2008; 98(3): 517-22. 
8. Kardas P. Compliance, clinical outcome, and quality of 
life of patients with stable angina pectoris receiving once-dai-
ly betaxolol versus twice daily metoprolol: a randomized 
controlled trial. Vasc Health Risk Manag 2007; 3(2): 235-42. 
9. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and 
elimination: dosing guidelines for altered renal function. 
Cancer Treatm Rev 1995; 21(1): 33-64. 
10. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, 
Chatelut E, Aapro M. International Society of Geriatric On-
cology (SIOG) recommendations for the adjustment of dos-
ing in elderly cancer patients with renal insufficiency. Eur J 
Cancer 2007; 43(1): 14-34.
11. Tu W, Morris AB, Li J et al. Association between adher-
ence measurements of metoprolol and health care utilization 
in older patients with heart failure. Clin Pharmacol Ther 
2005; 77(3): 189-201. 
12. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr, Von 
Hoff AL, Rozencweig M, Muggia FM. Risk factors for dox-
orubicin-induced congestive heart failure. Ann Intern Med 
1979; 91(5): 710-7. 
